Pharmaceuticals

M&A Roundup 2024: Q&A with Subin Baral

bexib
By bexib 0 Min Read

EY Global Life Sciences deals leaders discuss how the first half of 2024 performed compared to a strong end to 2023.

You Might Also Like

How do we prepare our pharmaceutical data for use with AI?

Prevounce Health Launches Mobile Phone-Enabled Remote Glucose Monitoring Device

New ‘plug-and-play’ system offers new way to administer vaccines and therapeutics

FDA Approves Incyte and Syndax Pharmaceuticals’ Nictimvo for Chronic Graft-Versus-Host Disease

Scemblix Demonstrates Major Molecular Response Improvements in Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Share This Article
Previous Article Survey shows most retail brands are ignoring X
Next Article Review: AnyCubic Kobra 3 – Manufacturer:
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Indian cash -free payments secure the $ 53 million US funded by PUBG Publisher Krafton.
Fintech
Late onboarding promotes clients’ losses at Singapore banks.
Fintech
The gorgeous spa Hotelgal Goma Resort will join the elegant hotel collection as the first member of the North Ireland
Hospitality & Tourism
Peter Navalo says, necessary for Trump’s economic success vision
Manufacturing